These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28131592)

  • 1. The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton's tyrosine kinase.
    Dai J; Wang C; Traeger SC; Discenza L; Obermeier MT; Tymiak AA; Zhang Y
    J Chromatogr A; 2017 Mar; 1487():116-128. PubMed ID: 28131592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
    Yip SH; Wu DR; Li P; Sun D; Watterson SH; Zhao R; Tino J; Mathur A
    J Chromatogr A; 2019 Feb; 1586():106-115. PubMed ID: 30578026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors.
    Perreault S; Chandrasekhar J; Patel L
    Acc Chem Res; 2022 Sep; 55(18):2581-2593. PubMed ID: 36069734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing stereoisomeric separation of an atropisomeric Bruton's tyrosine kinase inhibitor by using sub-2 µm immobilized polysaccharide-based chiral columns in supercritical fluid chromatography.
    He BL; Kleinsorge NG; Zhang L; Kleintop B
    J Chromatogr A; 2020 Aug; 1626():461320. PubMed ID: 32797816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatographic resolution of atropisomers for toxicity and biotransformation studies in pharmaceutical research.
    Yan TQ; Riley F; Philippe L; Davoren J; Cox L; Orozco C; Rai B; Hardink M
    J Chromatogr A; 2015 Jun; 1398():108-20. PubMed ID: 25937130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent encounters with atropisomerism in drug discovery.
    Glunz PW
    Bioorg Med Chem Lett; 2018 Jan; 28(2):53-60. PubMed ID: 29223590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atropisomerism in the Pharmaceutically Relevant Realm.
    Basilaia M; Chen MH; Secka J; Gustafson JL
    Acc Chem Res; 2022 Oct; 55(20):2904-2919. PubMed ID: 36153960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers.
    Carlsson AC; Karlsson S; Munday RH; Tatton MR
    Acc Chem Res; 2022 Oct; 55(20):2938-2948. PubMed ID: 36194144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparative chromatographic resolution of racemates using HPLC and SFC in a pharmaceutical discovery environment.
    Miller L; Potter M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(1):230-6. PubMed ID: 18639504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective chromatography in drug discovery.
    Zhang Y; Wu DR; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2005 Apr; 10(8):571-7. PubMed ID: 15837600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.
    Lanman BA; Parsons AT; Zech SG
    Acc Chem Res; 2022 Oct; 55(20):2892-2903. PubMed ID: 36178208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical strategies for successful enantioselective separation of atropisomeric polybrominated biphenyls 132 and 149 in environmental samples.
    Götsch A; Mariussen E; von der Recke R; Herzke D; Berger U; Vetter W
    J Chromatogr A; 2005 Jan; 1063(1-2):193-9. PubMed ID: 15700471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends and applications in liquid-phase chromatography enantioseparation of atropisomers.
    Peluso P; Mamane V; Aubert E; Cossu S
    Electrophoresis; 2017 Aug; 38(15):1830-1850. PubMed ID: 28168709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing atropisomer axial chirality in drug discovery.
    LaPlante SR; Edwards PJ; Fader LD; Jakalian A; Hucke O
    ChemMedChem; 2011 Mar; 6(3):505-13. PubMed ID: 21360821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
    Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vibrational circular dichroism (VCD) chiral assignment of atropisomers: application to γ-aminobutyric acid (GABA) modulators designed as potential anxiolytic drugs.
    Pivonka DE; Wesolowski SS
    Appl Spectrosc; 2013 Apr; 67(4):365-71. PubMed ID: 23601535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atropisomerism in medicinal chemistry: challenges and opportunities.
    Toenjes ST; Gustafson JL
    Future Med Chem; 2018 Feb; 10(4):409-422. PubMed ID: 29380622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supercritical fluid chromatography for the enantioseparation of pharmaceuticals.
    De Klerck K; Mangelings D; Vander Heyden Y
    J Pharm Biomed Anal; 2012 Oct; 69():77-92. PubMed ID: 22366324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of a two-dimensional liquid chromatography-supercritical fluid chromatography-mass spectrometry (2D-LC-SFS-MS) system to assess "in-vivo" inter-conversion of chiral drug molecules.
    Goel M; Larson E; Venkatramani CJ; Al-Sayah MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():89-95. PubMed ID: 29579733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.